Yazar "Kaplan, M. Ali" seçeneğine göre listele

Listeleniyor 1 - 20 / 20
  • Küçük Resim
    Öğe
    Approach to hypersplenism due to splenic metastasis of breast cancer: A case report
    (Dicle Üniversitesi Tıp Fakültesi, 2012) Küçüköner, Mehmet; Kaplan, M. Ali; İnal, Ali; Işıkdoğan, Abdurrahman; Fırat, Uğur; Önder, Akın; Uçmak, Feyzullah; Önder, Hakan; Akdoğan, M. Recai
    The most common sites for breast cancer metastasis include the bones, lungs, liver, lymph nodes, and brain. However, splenic metastasis of breast cancer is extremely rare. Hypersplenism occurs as a cause of severe hemolytic anemia in carcinomas or with marked splenic enlargement related to splenic metastasis. We presented a rare case of breast cancer with splenic metastasis that was undergone splenectomy to correct cytopenia related to hypersplenism. In the light of this case, splenectomy can be beneficial in the patients with hypersplenism.
  • [ X ]
    Öğe
    Cancer and thrombotic thrombocytopenic purpura
    (Ortadogu Ad Pres & Publ Co, 2008) Altintas, Abdullah; Cil, Timucin; Atay, A. Engin; Kaplan, M. Ali; Isikdogan, Abdurrahman; Ayyildiz, Orhan
    Thrombotic thrombocytopenic purpura (TTP) is a rare and fatal disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurologic disorder, renal function deterioration and fever. TTP may be idiopathic or secondary to autoimmune diseases, drugs, cancer and infections. Clinical findings of TTP are also present in cancer patients with disseminated intravascular coagulation and sepsis. TTP must be considered in the differential diagnosis in the case of concurrent microangiopathic hemolytic anemia and thrombocytopenia with or without leukoerythroblastic blood smear in cancer patients. Here we presented two patients who were followed up in our clinic with TTP secondary to metastatic breast cancer.
  • [ X ]
    Öğe
    Cisplatin-Based Therapy for the Treatment of Elderly Patients with Non-Small-Cell Lung Cancer: a Retrospective Analysis of a Single Institution
    (Asian Pacific Organization Cancer Prevention, 2012) Inal, Ali; Kaplan, M. Ali; Kucukoner, Mehmet; Urakci, Zuhat; Karakus, Abdullah; Isikdogan, Abdurrahman
    Background: In spite of the fact that platinum-based doublets are considered the standard therapy for patients with advanced non-small-cell lung cancer (NSCLC), no elderly-specific platinum based prospective phase III regimen has been explored. The aim of this retrospective singlecenter study was to evaluate the efficacy and side effects of cisplatin-based therapy specifically for the elderly. Methods: Patients receiving platinum-based treatment were divided into three groups. In the first group (GC), Gemcitabine was administrated at 1000 mg/m(2) on days 1, 8 and cisplatin was added at 75 mg/m(2) on day 1. In the second group (DC), 75 mg/m(2) docetaxel and cisplatin were administered on day 1. The third group (PC) received 175 mg of paclitaxel and 75 mg of cisplatin on day 1. These treatments were repeated every three weeks. Result: GC arm had 36, the DC arm 42 and the PC arm 29 patients. Grade III-IV thrombocytopenia was higher in the GC arm (21.2% received GC, 2.8% received DC, and 3.8% received PC), while sensory neuropathy was lower in patients with GC arm (3.0%, 22.2%, and 23.1% received GC, DC and PC, respectively). There were no statistically significant difference in the response rates among the three groups (p>0.05). The median Progression-free survival (PFS) was 5.0 months and the median Overall survival (OS) in each group was 7.1, 7.4 and 7.1 months, respectively (p>0.05). Conclusion: The response rate, median PFS and OS were similar among the three treatment arms. Grade III-IV thrombocytopenia was higher in the GC arm, while the GC regimen was more favorable than the other cisplatin-based treatmetns with regard to sensory neuropathy.
  • [ X ]
    Öğe
    COMPLEMENTARY AND ALTERNATIVE MEDICINE USAGE IN CANCER PATIENTS IN SOUTHEAST OF TURKEY
    (African Networks Ethnomedicines, 2013) Kucukoner, Mehmet; Bilge, Zulfikar; Isikdogan, Abdurrahman; Kaplan, M. Ali; Inal, Ali; Urakci, Zuhat
    The aim of this study was to investigate the frequency of complementary and alternative medicine (CAM) methods and clinical characteristics in cancer patients in southeast of Turkey. A total of 324 patients (173 female) were enrolled to this study. Questionnaire was applied to all patients individually for approximately 15 minutes by a doctor. At least one CAM method was used by 62% (n=201) of the patients. 82.5% (n=166) of patients treated with CAM were using at least one herbal species. Likewise, 40.9% (68/166) of these patients were using herbal mixtures and 39.8% (66/166) of them were using single herbal as nettle (Urtica dioica) or its seed, 19.3 % (32/166) of them were using other herbals. CAM methods were preferred more frequently by the patients with metastatic stage (p=0.005), receiving palliative treatment (p<0.001), chemotherapy (p=0.020), in between 40-60 ages patient groups (p=0.002), and when duration of disease was lengthened (p=0.002). CAM use among cancer patients is quite common. Presence of metastatic cancer at diagnosis, receiving chemotherapy and palliative treatment and long disease duration were found as main associated factors for CAM usage.
  • [ X ]
    Öğe
    The Correlation between Serum VEGF Levels and Known Prognostic Risk Factors in Colorectal Carcinoma
    (H G E Update Medical Publishing S A, 2014) Bestas, Remzi; Kaplan, M. Ali; Isikdogan, Abdurrahman
    Background/Aims: In the present study, we analyzed serum vascular endothelial growth factor (VEGF) levels and its correlation with the other clinicopathological characteristics of patients with colorectal carcinoma (CRC). Methodology: Seventy-one patients (F/M, 29/42; Mean age +/- SD, 53.3 +/- 13.1 years) were included. The results of serum VEGF were analysed with respect to stage, gender, age, CEA, metastases and topographical tumour localization. Results: Patients with stage 3-4 disease had significantly higher values of VEGF (253.41 pg/mL +/- 302.24) than patients with stage 1-2 (49.99 pg/L +/- 100.30) (P<0.003). Patients with the primary tumour localized in the colon had no significantly higher levels of serum VEGF than patients with the primary tumour localized in the rectum (225.97 +/- 324.88 pg/mL vs. 153.76 +/- 205.66 pg/mL, respectively, P = 0.269). The VEGF expression significantly correlated with serum CEA level (P <0.01) and clinical stages of colorectal cancer (P <0.01). The VEGF expression was not correlated with patients' age (P = 0.955) and gender (P = 0.740). Conclusions: The VEGF expression significantly correlated with advanced stage, and metastases but not age, gender, and tumour localization. VEGF may play an important role in the invasion and metastasis of CRC. Therefore, VEGF could be applied as prognostic markers in CRC.
  • [ X ]
    Öğe
    Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: A case report
    (Taylor & Francis Ltd, 2007) Cil, Timucin; Kaplan, M. Ali; Altintas, Abdullah; Pasa, Semir; Isikdogan, Abdurrahman
    [Abstract Not Available]
  • [ X ]
    Öğe
    Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer
    (Akad Doktorlar Yayinevi, 2013) Karaca, Halit; Geredeli, Caglayan; Kaplan, M. Ali; Demirci, Umut; Alici, Suleyman; Artac, Mehmet; Isikdogan, Abdurrahman
    Erlotinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, with single-agent antitumor activity which improves symptom control and quality of life compared with placebo in non-small-cell-lung cancer (NSCLC) patients. We aimed to determine the efficacy and safety of the second, third or fourth-line erlotinib in advanced NSCLC patients in Turkish population. Eighty patients (33 males and 47 females) were retrospectively evaluated. All patients had received a platinum-based regimen as the first-line metastatic therapy. Most of the patients (62.5%) had received erlotinib as the second-line treatment. None of the patients had EGFR mutation studied. One patient achieved a complete response, 10 patients partial response and 21 stable diseases. The overall response rate was 14% and disease control rate was 40%. The median progression-free survival (PFS) and overall survival (OS) were 12 months and 18 months, respectively. Although, there was no survival difference between male and female patients, the median PFS of females was significantly better than male patients (p=0.03). There was no significant difference in disease control rate in terms of age, smoking status, erlotinib line, performance status (PS), stage and skin rash. The most common adverse events were skin rash (56%), diarrhea (9%) and anorexia (8%). Sixteen patients (20%) developed grade 3 toxicities. Grade 4 toxicity or treatment related interstitial lung disease were not observed. Erlotinib showed an acceptable response rate, survival time and toxicity after disease progression with chemotherapy. It's an alternative therapy as a second or third-line therapy in patients with NSCLC. Prospective studies are needed to evaluate the efficiency of the treatment in Turkish population.
  • [ X ]
    Öğe
    Efficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO)
    (Asian Pacific Organization Cancer Prevention, 2014) Bozkurt, Oktay; Karaca, Halit; Ciltas, Aydin; Kaplan, M. Ali; Benekli, Mustafa; Sevinc, Alper; Demirci, Umut
    Background: There is no standard treatment for patients with colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment. Here we aimed to retrospectively evaluate the efficacy and tolerability of raltitrexed in combination with oral 5-fluoropyrimidine (uracil tegafur-UFT) or mitomycin C as salvage therapy in mCRC patients. Materials and Methods: A total of 62 patients who had received raltitrexed combined with UFT or mitomycin C were identified between December 2008 and June 2013. They were given raltitrexed 2.6 mg/m(2) (max 5 mg) i.v. on day 1 in combination with either oral UFT 500 mg/day on days 1-14 every 3 weeks (group A) or mitomycin C 6 mg/m(2) i.v. on day every 3 weeks (group B). Results: Forty-two patients (67.7%) were in group A and 20 (32.2%) in group B. In 15 patients (24%) grade 3/4 toxicity was observed, resulting in dose reduction, and in 13 patients (20.9%) dose delay was necessary. The median progression free survival (PFS) was 3 months (95% CI 2.65-3.34) and median overall survival (OS) was 6 months (95% CI 2.09-9.90) in the whole group. Median PFS was 3 months (95% CI 2.60-3.39) in group A vs 3 months (95% CI 1.64-4.35) in group B (p=0.90). Median OS was 6 months (95% CI 2.47-9.53) in group A vs 12 months (95% CI 2.83-21.1) in group B (p=0.46). Conclusions: The combination of raltitrexed with UFT or mitomycin C seem to be a salvage therapy option due to safety profile and moderate clinical activity in heavily-pretreated mCRC patients.
  • [ X ]
    Öğe
    Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases
    (Future Medicine LTD., 2021) Oruç, Zeynep; Kaplan, M. Ali; Karaağac, Mustafa; Özyurt, Neslihan; Tatlı, Ali Murat; Kaya, Ali Osman; Menekşe, Serkan; Kut, Engin; Koca, Sinan; Sever, Özlem Nuray; Yasin, İrem; Ebinç, Senar; Zeynelgil, Esra; Sakin, Abdullah; Turhal, Nazım Serdar; Işıkdoğan, Abdurrahman
    Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival. Lay abstract The optimal therapeutic option for castration-resistant prostate cancer (CRPC) patients with visceral metastases is unknown. We assessed the efficacy and tolerability of the first-line treatment options for CRPC patients with visceral metastasis. One hundred ninety-one patients diagnosed with CRPC with visceral metastases were included in the study. The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival between first-line docetaxel, abiraterone and enzalutamide treatments in CRPC patients with visceral metastases. For patients who cannot undergo chemotherapy, enzalutamide, among novel androgen pathway inhibitors, may be the most appropriate option, given its numerical, although statistically insignificant, difference in overall survival and its fewer side effects compared with abiraterone.
  • [ X ]
    Öğe
    Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
    (Elsevier Espana Slu, 2014) Inal, Ali; Kaplan, M. Ali; Kucukoner, Mehmet; Urakci, Zuhat; Kilinc, Faruk; Isikdogan, Abdurrahman
    Background: It has been demonstrated that there are a lot of different prognostic factors which Non-small cell lung are worthy of consideration whereas diabetes mellitus (DM) has not been clearly or consistently identified as a prognostic value in advanced non-small cell lung cancer (NSCLC). The aim Prognostic factors of this study was to investigate the prognostic significance of the characteristics of patients in advanced NSCLC. Specifically, we investigated the impact of DM for progression-free survival (PFS) and overall survival (OS) in patients receiving first-line platinum-based doublets chemotherapy. Methods: We retrospectively reviewed 442 patients with advanced NSCLC. DM and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for OS were identified as having prognostic significance: performance status (p < 0.001), stage (p < 0.001), DM (p < 0.001), liver metastasis (p = 0.02) and brain metastasis (p < 0.001). Stage, diabetes mellitus, and liver metastasis were identified as having prognostic significance for PFS. Multivariate analysis showed that poor performance status, presence of DM and advanced stage were considered independent negative prognostic factors for OS (p 0.001, p < 0.001 and p < 0.001 respectively). Furthermore, DM and stage were considered independent negative prognostic factors for PFS (p 0.005 and p 0.001 respectively). Conclusion: In conclusion, DM at the time of diagnosis was associated with the negative prognostic importance for PFS and OS in the advanced stage patients who were receiving first-line platinum-based doublets chemotherapy. In addition poor performance status and advanced stage were identified as negative prognostic factors. (c) 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.
  • [ X ]
    Öğe
    Is Diabetes Mellitus a Prognostic Factor for Survival in Patients with Small Cell Lung Cancer?
    (Asian Pacific Organization Cancer Prevention, 2012) Inal, Ali; Kaplan, M. Ali; Kucukoner, Mehmet; Urakci, Zuhat; Karakus, Abdullah; Nas, Necip; Guven, Mehmet
    Background: Previous studies have pointed to many different prognostic factors for small cell lung cancer (SCLC) but diabetes mellitus (DM) has not been clearly or consistently identified as of prognostic value. The aim of this study was to investigate the prognostic significance of the characteristics of patients and clinical laboratory tests in SCLC. Specifically, we investigated that the impact of DM for survival in the patients receiving first-line etoposide plus cisplatin (EP) chemotherapy. Methods: We retrospectively reviewed 161 patients with SCLC with a focus on DM and other potential prognostic variables were chosen for univariate and multivariate analyses with respect to survival. Result: Among the sixteen variables of univariate analysis, five were identified to have prognostic significance: performance status (PS) (p < 0.001), stage (p=0.001), DM (p=0.005), serum albumin (p < 0.001) and hemoglobin levels (p=0.03). Multivariate analysis showed PS, stage and serum albumin level to be independent prognostic factors for survival (p=0.02, p=0.02 and p=0.009 respectively), but DM was not an independnet factor. Conclusion: In conclusion, PS, stage and serum albumin level were identified as important prognostic factors, while DM at the time of diagnosis of SCLC did not have prognostic importance for survival.
  • Küçük Resim
    Öğe
    A Low body fat mass ratio predicts poor prognosis in patients with advanced non-small cell lung cancer
    (Routledge Journals Taylor & Francis Ltd., 2022) Oruç, Zeynep; Akbay, Ahmet; Kaplan, M. Ali; Oruç, İdris; Urakçı, Zuhat; Küçüköner, Mehmet; Işıkdoğan, Abdurrahman
    Purpose The aim of this study was to investigate the effect of the body fat mass ratio on survival and prognosis in advanced non-small-cell lung cancer patients. Methods The study includes 200 patients who were diagnosed with advanced non-small-cell lung cancer between 2014 and 2018 and whose body fat mass percentage and body mass index (BMI) were determined using the Tanita Body Composition Analyzer during admission. Results All patients had advanced incurable non-small-cell lung cancer (30% had locally advanced disease, 70% were stage IV). In the univariate and multivariate analyses, age, gender, histopathological type, smoking history, comorbidities, weight loss in the last six months and body mass index had no statistically significant effect on survival (p > 0.05). However, the performance status (p = 0.008), metastatic status (p = 0.003) and body fat mass ratio (p = 0.01) were found to have a significant effect on overall survival (OS): the median OS was 16.4 mo, in patients with the BFM ratio <= 22% and 29.2 mo, in those with > 22% (p = 0.01). Conclusion In this study, it was found that the body fat mass ratio was an important prognostic factor in patients with advanced non-small-cell lung cancer.
  • Küçük Resim
    Öğe
    Malign mezotelyomada eser element ve oksidatif parametrelerin düzeyi
    (İstanbul Medeniyet Üniversitesi Tıp Fakültesi, 2012) Evliyaoğlu, Osman; Abakay, Abdurrahman; Tanrıkulu, A. Çetin; Palancı, Yılmaz; Sezgi, Cengizhan; Şen, Hadice; Küçüköner, Mehmet; Kaplan, M. Ali; Şenyiğit, Abdurrahman
    Öz:Malign Plevral Mezotelyoma (MPM) kötü prognoza sahip bir kanser türüdür ve hastaların yalnızca az bir kısmı tedaviden yarar görür. Eser elementler birçok hastalığın patogenezinde doğrudan veya dolaylı olarak rol oymaktadır. Bu çalışmada MPM hastalarında eser element ve oksidatif parametrelerin düzeyinin araştırılması amaçlanmıştır. Üniversite hastanesinde takip edilen 48 MPM hastası ve herhangi bir kronik hastalığı olmayan 52 kontrol olgusu çalışmaya alınmıştır. Çalışmaya 24 erkek ve 24 kadın hasta dahil edilmiştir. MPM hastalarının yaş ortalaması 55,8 yıldı. Toplam 39 hastanın asbest teması vardı (% 81,3) ve ortalama asbest temas süresi 34 yıldı. Toplam 33 hastada epitelyal tip (% 68,8) saptandı. Plevral sıvı sitolojisi ise 13 hastada pozitifti (% 27,1). Eser element seviyelerine bakıldığında Bakır (Cu) düzeyi MPM hastalarında kontrol grubuna göre yüksek saptandı. Çinko (Zn) düzeyleri arasında ise her iki grup arasında fark yoktu (Tablo 1). Ayrıca Malonil dialdehit (MDA) düzeyleri MPM grubunda yüksek ve Nitrik oksit (NO) ise MPM grubunda düşük olarak saptandı (Tablo 1). MPM hastalığında hastalığın takibinde ve prognozda eser element ve oksidatif parametrelerin rolleri konusunda geniş serili çalışmalara gereksinim vardır.
  • [ X ]
    Öğe
    Multiple primary malignant neoplasms: Multi-center results from Turkey
    (Imprimatur Publications, 2012) Babacan, N. A.; Aksoy, S.; Cetin, B.; Ozdemir, N. Y.; Benekli, M.; Uyeturk, U.; Kaplan, M. Ali
    Purpose: Multiple primary malignant neoplasms (MPMNs) are defined as a diagnosis of two or more independent primary malignancies of different histologies/origins in an individual. The frequency of MPMN is being increasing. In this study we aimed to determine the frequency and clinical features of second primary cancers (SPCs). Methods: From January 1990 to December 2010, patients with MPMNs were screened in 5 centers. Data were obtained retrospectively from hospital charts. Results: Three hundred seventy-seven patients with MPMNs were evaluated. The median age at initial cancer diagnosis was 61 years (range 18-88). The median age at second cancer was 64 years (range 20-89). The median time between two cancer diagnoses was 15 months (range 0-504). Male to female ratio was 1.44 (M/F 223/154). The most frequent initial cancer types were head and neck (54 patients, 14.3%), breast (54 patients, 14.3%), and colorectal (43 patients, 11.4%). The most frequent second cancer types were lung (76 patients, 20.2%), colorectal (39 patients, 10.3%) and breast (33 patients, 8.8%). The most common cancer pairs in females were breast-gynecologic cancers (15 patients, 9.7%), colorectal-breast cancers (9 patients, 5.8%) and breast-colorectal cancers (7 patients, 4.5%). The most common cancer pairs in males were head and neck-lung cancers (29 patients, 13%), bladder-lung cancers (9 patients, 4%), and bladder-prostate cancers (7 patients, 3%). The median follow up was 36 months (range 1-595). Conclusion: Physicians should be aware of SPCs probabilities. Newly developed suspicious lesions should be evaluated rigorously. Histopathologic evaluations of suspicious lesions for second tumors should be used extensively if needed. In our series, the most common pairs were breast-gynecologic cancers in females and head and neck-lung cancers in males.
  • [ X ]
    Öğe
    Nasal septum perforation in the patients with advanced breast cancer due to the treatment of lapatinib+capecitabine
    (Kare Publ, 2015) Oruc, Zeynep; Kucukoner, Mehmet; Urakci, Zuhat; Kaplan, M. Ali; Solmaz, Ihsan; Isikdogan, Abdurrahman
    Nasal septum perforation is a rare complication that can occur due to certain antineoplastic agents, especially antiangiogenic agents such as bevacizumab. There has been no case of nasal perforation case due to the treatment of lapatinib+capecitabine so far. Our case is nasal septum perforation occuring with the 38-year-old patient diagnosed with premenopausal advanced breast cancer during the treatment of lapatinib+capecitabine. It occured as epistaxis in the 30th month of patient's treatment. In the anterior rhinoscopy, nasal septum perforation was diagnosed. The patient had no nasal irritant or cocaine, or no trauma story. Although it is a rare complication, perforation due to lapatinib+capecitabine should be considered in the advanced breast cancer patients with the treatment of lapatinib+capecitabine when nasal symptoms (epistaxis, nasal congestion, local pain, irritation, rhinorrhea) occur.
  • [ X ]
    Öğe
    Prognostic Factors for Second-line Treatment of Advanced Non-small-cell Lung Cancer: Retrospective Analysis at a Single Institution
    (Asian Pacific Organization Cancer Prevention, 2012) Inal, Ali; Kaplan, M. Ali; Kucukoner, Mehmet; Urakci, Zuhat; Karakus, Abdullah; Isikdogan, Abdurrahman
    Background: Platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC) is still considered the first choice, presenting a modest survival advantage. However, the patients eventually experiance disease progression and require second-line therapy. While there are reliable predictors to identify patients receiving first-line chemotherapy, very little knowledge is available about the prognostic factors in patients who receive second-line treatments. The present study was therefore performed. Methods: We retrospectively reviewed 107 patients receiving second-line treatments from August 2002 to March 2012 in the Dicle University, School of Medicine, Department of Medical Oncology. Fourteen potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for overall survival (OS) were identified to have prognostic significance: performance status (PS), stage, response to firs-line chemotherapy, response to second-line chemotherapy and number of metastasis. PS, diabetes mellitus (DM), response to first-line chemotherapy and response to second-line chemotherapy were identified to have prognostic significance for progression-free survival (PFS). Multivariate analysis showed that PS, response to first-line chemotherapy and response to second-line chemotherapy were considered independent prognostic factors for OS. Furthermore, PS and response to second-line chemotherapy were considered independent prognositc factors for PFS. Conclusion: In conclusion, PS response to first and second-line chemotherapy were identified as important prognostic factors for OS in advanced NSCLC patients who were undergoing second-line palliative treatment. Furethermore, PS and response to second-line chemotherapy were considered independent prognostic factors for PFS. It may be concluded that these findings may facilitate pretreatment predication of survival and can be used for selecting patients for the correct choice of treatment.
  • [ X ]
    Öğe
    Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study
    (Asian Pacific Organization Cancer Prevention, 2012) Inal, Ali; Kaplan, M. Ali; Kucukoner, Mehmet; Urakci, Zuhat; Guven, Mehmet; Nas, Necip; Yunce, Muharrem
    Background: The majority of patients with gastric cancer in developing countries present with advanced disease. Systemic chemotherapy therefore has limited impact on overall survival. Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyze prognostic factors for survival in advanced gastric cancer patients undergoing first-line palliative chemotherapy. Methods: We retrospectively reviewed 107 locally advanced or metastatic gastric cancer patients who were treated with docetaxel and cisplatin plus fluorouracil (DCF) as first-line treatment between June 2007 and August 2011. Twenty-eight potential prognostic variables were chosen for univariate and multivariate analyses. Results: Among the 28 variables of univariate analysis, nine variables were identified to have prognostic significance: performance status, histology, location of primary tumor, lung metastasis, peritoneum metastasis, ascites, hemoglobin, albumin, weight loss and bone metastasis. Multivariate analysis by Cox proportional hazard model, including nine prognostic significance factors evident in univariate analysis, revealed weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level to be independent variables. Conclusion: Performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level were identified as important prognostic factors in advanced gastric cancer patients. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.
  • [ X ]
    Öğe
    RETINOIC ACID SYNDROME SUBSEQUENT TO THE FIRST DOSE OF ALL TRANS RETINOIC ACID
    (Elsevier Science Inc, 2008) Altintas, Abdullah; Pasa, Semir; Cil, Timucin; Kaplan, M. Ali; Ayyildiz, Orhan
    [Abstract Not Available]
  • [ X ]
    Öğe
    Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study
    (Asian Pacific Organization Cancer Prevention, 2012) Altinbas, Mustafa; Kalender, Mehmet Emin; Oven, Basak; Sevinc, Alper; Karaca, Halit; Kaplan, M. Ali; Alici, Suleyman
    Aim: To evaluate efficacy and tolerability of topotecan treatment for recurrent small cell lung carcinoma. Patients and Methods: A total of 62 patients were evaluated retrospectively. Statistical analysis was performed using GraphPad Instat (version 3.05). Results: DFifty five of patients (89%) were male and 7 (11%) were female. Median age was 56.7 +/- 9.3 (34-75). Forty eight of patients (80%) were extensive stage (ES) at the time of diagnosis. Fifty of the patients (80.6 Medical Oncology Clinic) were given median 5.36 cycles of cisplatin-etoposide (2-8 cycles). Time to recurrence was 15.6 +/- 6.13 weeks in patients with limited stage (LS) and 6.3 +/- 3.82 weeks in extensive stage (ES) (p<0.0001). Overall survival was 14.0 +/- 6.08 months in ES and 17.9 +/- 6.88 months in LS. The difference between two groups was statistically meaningful (p=0.0447). The overall survival of the patients was 14.8 +/- 6.43 months (4.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171). In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Conclusion: Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.
  • Küçük Resim
    Öğe
    Yağsız vücut kitlesini içeren yeni bir formül ile glomerüler filtrasyon hızı tayini
    (2017) Kaplan, M. Ali; Özmen, Şehmus
    Giriş: Glomeruler filtration hızını (GFH) doğru hesaplamak böbrek hastalığının şiddetini göstermede, dialize başlama zamanına karar vermede ve doğru ilaç dozu ayarlamada fayda sağlar. Serum kreatinini (SKr) renal fonksiyon göstergesi olarak yaygın olarak kullanılmakla birlikte GFH dışındaki faktörlerden de etkilenmektedir. Biz bu çalışmada demografik ve antropometrik değişkenlerin GFH'na etkisini araştırdık ve yağsız vücut kitlesini (YVK) içeren yeni bir GFH hesaplama yöntemi geliştirmeyi amaçladık. Gereç ve yöntem: Çalışmaya kronik böbrek hastası (ortalama GFH 38,2 ± 28,2 ml/dk/1.73m2) 81 olgu (ortalama yaş 43,4±17,2) alındı. Gerçek GFH Tc-99m DTPA ile ölçüldü. YVK bioelektrik impedans analizi ile ölçüldü. Formüller elde edilirken doğrusal regresyon analizi kullanıldı. Bulgular: Doğrusal regresyon analizi kullanılarak farklı BMI gruplarında GFH'nın bağımsız değişkenleri obez olmayan grupta (BMI<30 kg/m2) 1/serum kreatinin, obez grupta (BMI>30kg/m2) YVK/SKr ve YK/SKr bulundu. Yaş, cinsiyet, kilo, boy, albumin ve 24 saatlik idrar protein atılımının ise GFH'nı etkilemediği gözlendi (p>0,05). Doğrusal regresyon analizi kullanılarak obez olmayan grupta [GFR=74,7/kr +1 (hasta erkekse) veya -3,5 (hasta kadınsa)] ve obez grupta [GFH=(1,255xYVK?0,825xVYK)/kr + 2,1 (hasta kadınsa) veya + 11,4 (hasta erkekse)] iki ayrı formül elde edildi. Yeni formül Tc-99m DTPA referans alınarak değerlendirildiğinde tahmin katsayısı (R2): 0,828 bulundu (p<0,05). Yeni formül, Cockcroft and Gault (C&G), YVK eklenmiş C&G (C&G-YVK), Modification of Diet in Renal Disease (MDRD) formülü, kreatinin klirensi (KrKl) ile karşılaştırıldığında daha iyi sonuçlar elde edildi. Sonuç: Yeni formül, diğer yaygın kullanılan formüllerle karşılaştırıldığında GFH'nı daha doğru hesaplamaktadır. Obez olgularda GFH'nı hesaplamada vücut kompozisyonu önemli bir etkiye sahiptir. Bu hastalarda geleneksel formüllerle GFR tayini yapılırken dikkatli olunmalıdır. Anahtar kelimeler: glomerüler filtrasyon hızı, kronik böbrek hastalığı, kreatinin, yağsız vücut kitlesi